Difference between revisions of "Talk:Case 52"

From Libre Pathology
Jump to navigation Jump to search
(? broader range of IHC for this case)
 
(changes made)
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
The list of IHC for which Dr Torres asks why includes the following choices that I think are reasonable  
The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable  
CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
*CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
*Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
*PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
::[https://librepathology.org/w/index.php?title=Case_52&diff=47416&oldid=29649 Changes were made] to the case as result of the comments. [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 12:10, 23 May 2017 (EDT)

Latest revision as of 16:11, 23 May 2017

The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable

  • CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
  • Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
  • PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
Changes were made to the case as result of the comments. Michael (talk) 12:10, 23 May 2017 (EDT)